/var/www/perpustakaan972/lib/SearchEngine/DefaultEngine.php:610 "Search Engine Debug 🔎 🪲"
Engine Type ⚙️: "SLiMS\SearchEngine\DefaultEngine"
SQL ⚙️: array:2 [ "count" => "select count(distinct b.biblio_id) from biblio as b left join mst_publisher as mp on b.publisher_id=mp.publisher_id left join mst_place as mpl on b.publish_place_id=mpl.place_id where b.opac_hide=0 and (b.biblio_id in(select ba.biblio_id from biblio_author as ba left join mst_author as ma on ba.author_id=ma.author_id where ma.author_name like ?))" "query" => "select b.biblio_id, b.title, b.image, b.isbn_issn, b.publish_year, mp.publisher_name as `publisher`, mpl.place_name as `publish_place`, b.labels, b.input_date, b.edition, b.collation, b.series_title, b.call_number from biblio as b left join mst_publisher as mp on b.publisher_id=mp.publisher_id left join mst_place as mpl on b.publish_place_id=mpl.place_id where b.opac_hide=0 and (b.biblio_id in(select ba.biblio_id from biblio_author as ba left join mst_author as ma on ba.author_id=ma.author_id where ma.author_name like ?)) order by b.last_update desc limit 10 offset 0" ]
Bind Value ⚒️: array:1 [ 0 => "%Sampeliling, A.%" ]
Arround 10 percent NIDDM patients will develope secondary failure every year. Acarbose could lower the absorbtion of glucose from the intestines. The aim of the study is to evaluate the benefit of acorbose as adjuvant treatment to NIDDM with secondary failure to glibenclamide. Patients were secondary failure to glibenclamide include to the study. The study was done in two phases. First phase: t…